Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of HIV status and vaccination on long COVID conditions within an integrated health care system.

Communications medicine·2026
Same author

Impact of SARS-CoV-2 Breakthrough Infection on Short-Term CD4 Count Among Adults With HIV in the United States From 2020 to 2022.

Open forum infectious diseases·2026
Same author

Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.

The New England journal of medicine·2026
Same author

Patient-Directed Discharge Among Hospitalized Persons With Opioid Use Disorder in the Fentanyl Era: A Scoping Review.

American journal of medicine open·2026
Same author

New to Cohort, Not New to Care: Leveraging Historical Data in HIV Clinical Cohorts in the United States.

American journal of epidemiology·2026
Same author

Projected Increase in HIV Incidence in 11 States if Ryan White Ends: A Simulation Study.

American journal of public health·2026

Related Experiment Video

Updated: Jul 18, 2026

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
07:27

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty

Published on: October 6, 2016

HIV and aging: implications for patient management.

Kelly A Gebo1

  • 1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA. kgebo@jhmi.edu

Drugs & Aging
|November 18, 2006
PubMed
Summary

The percentage of HIV cases in adults over 50 has risen significantly, driven by longer lifespans with treatment and new infections. Older patients may experience reduced benefits and increased toxicity from highly active antiretroviral therapy (HAART).

More Related Videos

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Related Experiment Videos

Last Updated: Jul 18, 2026

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
07:27

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty

Published on: October 6, 2016

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Area of Science:

  • Geriatric Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • HIV prevalence is increasing in patients aged 50 years and older.
  • This trend is due to increased longevity with highly active antiretroviral therapy (HAART) and new infections in older adults.
  • Older individuals face unique challenges with HAART, including potential for reduced immunological benefits and increased toxicities.

Purpose of the Study:

  • To highlight the growing concern of HIV in older populations.
  • To discuss the complexities of managing HIV in aging patients, including comorbidities and drug interactions.
  • To emphasize the need for further research into HAART effectiveness and outcomes in older adults.

Main Methods:

  • Review of existing literature on HAART in older HIV patients.
  • Analysis of trends in HIV prevalence among different age groups.
  • Consideration of factors impacting HAART efficacy and toxicity in the elderly.

Main Results:

  • HIV cases in patients aged 50+ increased from 17% to 23% between 2001 and 2004.
  • Older patients may achieve virological suppression but potentially with diminished immunological gains compared to younger patients.
  • Increased risk of HAART-related toxicities, especially with renal or hepatic insufficiency, is a concern in older HIV patients.

Conclusions:

  • Healthcare providers must carefully select HAART regimens for older patients, considering comorbidities, drug-drug interactions, and potential adverse effects.
  • Routine health screenings are crucial for older HIV patients due to increased longevity and malignancy risks.
  • Further controlled trials are needed to understand HIV epidemiology, pathogenesis, and therapeutic outcomes in the aging HIV population.